We have written before about Amazon's APEX procedure and how it could help patent owners take down infringing products found for sale on Amazon. Amazon Patent Evaluation Express (APEX) – A Cost-Effective Alternative to Litigation | Harness IP. In this post we discuss how the APEX program can also be used to address instances of indirect infringement, where the Amazon seller causes the buyer to infringe a patent. Amazon's APEX Program In recent years, Amazon [...]

On January 16, 2026, the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (“PTAB”) instituted two inter partes review (IPR) proceedings for Brooks Kushman client Ford Motor Company (“Ford”) and denied Patent Owner AutoConnect Holdings, LLC's request for discretionary denial in a third proceeding. See IPR2025‑01342, ‑01383, and ‑01524, Paper 11 (Jan. 16, 2026). Ford filed these IPRs challenging patents related to infotainment systems that AutoConnect asserted in district court. These decisions are especially significant given [...]

In Seagen v. Daiichi Sankyo1, the Federal Circuit invalidated claims in a life sciences patent, highlighting the limits of genus-level disclosure to support specific, non-exemplified species. The court found that generic disclosure of a small linker in antibody-drug conjugates (ADCs) of Seagen's application was not enough to describe the particular linker of Daiichi Sankyo's ADC, Enhertu®, and reversed a jury verdict that Enhertu® infringed Seagen's patent. The decision reinforces the demanding written description standard in [...]